View Post

CRISPR gene editing may halt progression of triple-negative breast cancer

In In The News by Barbara Jacoby

Source: Boston Children’s Hospital From: eurekalert.org A tumor-targeted CRISPR gene editing system, encapsulated in a nanogel and injected into the body, could effectively and safely halt the growth of triple-negative breast cancer, report researchers at Boston Children’s Hospital. Their proof-of-principle study, conducted in human tumor cells and in mice, suggests a potential genetic treatment for triple-negative breast cancer, which has …

View Post

Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn into Oncology

In Clinical Trials by Barbara Jacoby

Source: CytoDyn Inc. From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the injection of the first patient with metastatic triple-negative breast cancer (“mTNBC”).  The patient will be treated with leronlimab by Jacob Lalezari, M.D., currently Chief Executive …

View Post

Keytruda Plus Chemo Shows High Response Rate in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: specialtypharmacytimes.com Pembrolizumab (Keytruda, Merck) plus chemotherapy demonstrated a statistically significant improvement in pathological complete response rate (pCR) as a neoadjuvant therapy in patients with triple-negative breast cancer (TNBC), according to new data from a phase 3 study. Approximately 15% to 20% of patients with breast cancer are diagnosed with TNBC, which can be more difficult to treat than other …

View Post

Merck Data Are Another Step for Immunotherapy in Breast Cancer

In Clinical Trials by Barbara Jacoby

From: xconomy.com Merck this morning announced that a combination of its drug pembrolizumab (Keytruda) and chemotherapy succeeded in a Phase 3 study in breast cancer, a potentially notable advance for immunotherapy in treating the disease. Merck (NYSE: MRK) said that Keytruda and chemotherapy beat chemo alone when given to patients with triple-negative breast cancer in a study called Keynote-522. The …

View Post

Zhang group identifies gene that may make triple-negative breast cancer cells vulnerable to existing drug

In In The News by Barbara Jacoby

Source: University of Notre Dame From: newswise.com Certain therapies that have proven effective in treating some types of breast cancers are ineffective for women diagnosed with triple-negative breast cancer (TNBC). In fact, there is limited targeted drug therapy for this type of breast cancer — the most aggressive type, diagnosed in about 20 percent of breast cancer patients. But a …

View Post

Study Confirms Disparities in Triple-Negative Breast Cancer Diagnoses

In In The News by Barbara Jacoby

Source: Wiley Research News From: prnewswire.com A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, shows that women of color and young women may face elevated risks of developing triple-negative breast cancers, which are often aggressive and do not respond to hormone therapy or targeted therapy. Previous U.S. studies have found racial disparities in triple-negative …

View Post

Maria Lewis

In In The News by Barbara Jacoby

Two years ago in the summer of 2017, Maria Lewis from Salt Lake City was told by her oncologist at a large local cancer institute that she had Triple Negative breast cancer. She was given three to six months to live with little hope of any treatment working. The cancer institute offered a counselor to discuss getting her affairs in order.  But Maria …

View Post

Jefferson researcher discovers a population of bone cells that subdues cancer

In In The News by Barbara Jacoby

Source: jefferson.edu From: news-medical.net In breast cancer, there are cases of women and men whose cancer returns in their bones 20-30 years after they were treated for their primary disease and thought they were cancer-free. This phenomenon always puzzled Jefferson researcher Karen Bussard, PhD. How is it possible that breast cancer cells from a primary tumor are able to reach …

View Post

ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1

In Clinical Trials by Barbara Jacoby

From: physiciansweekly.com Latest analysis from IMpassion trial confirms need for testing One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies, and that message came through loud and clear during an oral abstract session devoted to treatment of …

View Post

IU Precision Health Initiative has dramatic results for triple negative breast cancer patient

In Clinical Trials by Barbara Jacoby

By: Christine Drury From: iu.edu Five years ago, Jackie Stephens rolled over in bed and felt a horrible pain in her right breast. A subsequent mammogram revealed a large lump in her right breast and two smaller ones. Her diagnosis: triple negative breast cancer. Stephens’ oncologist prescribed a treatment regimen of chemotherapy, a lumpectomy and radiation. When her treatment was …